Astellas Turns Up Heat On Bid To Acquire CV Therapeutics
This article was originally published in PharmAsia News
Executive Summary
Following CV Therapeutics' refusal to accept its $16 per share purchase bid, Astellas is trying to turn up the pressure on CVT with a two-pronged approach involving both a tender offer for outstanding shares and a lawsuit in Delaware Chancery Court